MARKET

ZBIO

ZBIO

Zenas BioPharma Inc.
NASDAQ
18.21
-3.95
-17.82%
After Hours: 18.00 -0.21 -1.15% 19:39 03/27 EDT
OPEN
19.23
PREV CLOSE
22.16
HIGH
19.35
LOW
17.20
VOLUME
3.37M
TURNOVER
--
52 WEEK HIGH
44.60
52 WEEK LOW
6.11
MARKET CAP
1.04B
P/E (TTM)
-2.1564
1D
5D
1M
3M
1Y
5Y
1D
Zenas BioPharma (ZBIO) Valuation Check After New Convertible Notes And Equity Offerings
Simply Wall St · 2d ago
Zenas BioPharma Tumble on Pricing of Convertible-Note, Stock Public Offerings
Dow Jones · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services
Reuters · 2d ago
BUZZ-Zenas BioPharma slides on $300 mln convertible bond, stock sales
Reuters · 2d ago
Zenas Biopharma, Daqo New Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Benzinga · 2d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 2d ago
Zenas BioPharma 5M share Spot Secondary priced at $20.00
TipRanks · 2d ago
Why Newsmax Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Benzinga · 2d ago
More
About ZBIO
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for patients with autoimmune diseases. The Company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.

Webull offers Zenas BioPharma Inc. stock information, including NASDAQ: ZBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZBIO stock methods without spending real money on the virtual paper trading platform.